三氧化二砷治疗白血病联合治疗方案概述：基本概念与临床意义
An overview of arsenic trioxide-involved combined treatment algorithms for leukemia: basic concepts and clinical implications.
作者信息
Jiang Yanan, Shen Xiuyun, Zhi Fengnan, Wen Zhengchao, Gao Yang, Xu Juan, Yang Baofeng, Bai Yunlong
机构信息
Department of Pharmacology (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, China.
Translational Medicine Research and Cooperation Center of Northern China, Heilongjiang Academy of Medical Sciences, Harbin, China.
出版信息
Cell Death Discov. 2023 Jul 27;9(1):266. doi: 10.1038/s41420-023-01558-z.
Arsenic trioxide is a first-line treatment drug for acute promyelocytic leukemia, which is also effective for other kinds of leukemia. Its side effects, however, limit its clinical application, especially for patients with complex leukemia symptoms. Combination therapy can effectively alleviate these problems. This review summarizes the research progress on the combination of arsenic trioxide with anticancer drugs, vitamin and vitamin analogs, plant products, and other kinds of drugs in the treatment of leukemia. Additionally, the new progress in arsenic trioxide-induced cardiotoxicity was summarized. This review aims to provide new insights for the rational clinical application of arsenic trioxide.
三氧化二砷是急性早幼粒细胞白血病的一线治疗药物，对其他类型的白血病也有效。然而，其副作用限制了它的临床应用，尤其是对于白血病症状复杂的患者。联合治疗可以有效缓解这些问题。本文综述了三氧化二砷与抗癌药物、维生素及维生素类似物、植物制品和其他各类药物联合治疗白血病的研究进展。此外，还总结了三氧化二砷所致心脏毒性的新进展。本文旨在为三氧化二砷的合理临床应用提供新的见解。
Zotero 插件